Wells Fargo & Company Has Lowered Expectations for Boston Scientific (NYSE:BSX) Stock Price

Key Points

• Wells Fargo cut Boston Scientific’s price target from $48 to $45 and maintained an “equal weight” rating, citing implied upside of 6.51% from the prior close.
• Analyst sentiment has become more cautious, with several firms downgrading the stock or lowering targets, although the overall consensus remains “Moderate Buy” with a $63.50 target.
• Boston Scientific met quarterly EPS expectations and exceeded revenue estimates, but investors face pressure from a cybersecurity outage, reduced full-year guidance, contracting margins and weaker demand in some markets.

Boston Scientific (NYSE:BSX - Get Free Report) had its target price cut by analysts at Wells Fargo & Company from $48.00 to $45.00 in a report issued on Thursday, Benzinga reports. The firm currently has an "equal weight" rating on the medical equipment provider's stock. Wells Fargo & Company's price target suggests a potential upside of 6.51% from the company's previous close.

Several other analysts also recently commented on the company. Jefferies Financial Group downgraded Boston Scientific from a "buy" rating to a "hold" rating and set a $46.00 price objective for the company. in a research note on Wednesday. Argus cut Boston Scientific from a "buy" rating to a "hold" rating in a research report on Friday, July 31st. Rothschild & Co Redburn cut their target price on Boston Scientific from $106.00 to $78.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $60.00 price target (down from $75.00) on shares of Boston Scientific in a report on Thursday, July 30th. Finally, UBS Group lowered their price target on Boston Scientific from $74.00 to $67.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Boston Scientific currently has a consensus rating of "Moderate Buy" and a consensus target price of $63.50.

Boston Scientific Stock Down 0.4%

Shares of NYSE:BSX traded down $0.18 during midday trading on Thursday, hitting $42.25. 3,187,582 shares of the company's stock were exchanged, compared to its average volume of 18,595,738. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific has a 12 month low of $39.57 and a 12 month high of $105.65. The company has a market cap of $61.23 billion, a PE ratio of 17.09, a price-to-earnings-growth ratio of 1.10 and a beta of 0.58. The stock has a 50 day moving average price of $45.12 and a 200-day moving average price of $57.43.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. The business had revenue of $5.14 billion for the quarter, compared to analysts' expectations of $5.07 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 EPS. On average, sell-side analysts anticipate that Boston Scientific will post 3.21 EPS for the current fiscal year.

Insider Activity

In other Boston Scientific news, Director David C. Habiger purchased 2,100 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company's stock, valued at $816,644.40. The trade was a 13.94% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward J. Ludwig acquired 5,000 shares of the business's stock in a transaction on Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 194,522 shares of company stock valued at $9,385,210 over the last three months. Corporate insiders own 0.34% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

Large investors have recently made changes to their positions in the business. Avantax Planning Partners Inc. lifted its holdings in Boston Scientific by 4.0% in the first quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider's stock valued at $329,000 after acquiring an additional 201 shares during the last quarter. WPG Advisers LLC grew its position in Boston Scientific by 11.9% in the first quarter. WPG Advisers LLC now owns 1,916 shares of the medical equipment provider's stock worth $120,000 after acquiring an additional 203 shares during the period. Natural Investments LLC grew its position in Boston Scientific by 1.3% in the second quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider's stock worth $685,000 after acquiring an additional 206 shares during the period. 180 Wealth Advisors LLC increased its stake in Boston Scientific by 3.6% during the first quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider's stock worth $406,000 after acquiring an additional 223 shares during the last quarter. Finally, MGO One Seven LLC increased its stake in Boston Scientific by 1.9% during the third quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider's stock worth $614,000 after acquiring an additional 260 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported third-quarter revenue of $5.138 billion, ahead of the $5.07 billion consensus estimate, while adjusted EPS of $0.73 matched expectations. Revenue increased approximately 1.5% year over year. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Management reiterated its long-term growth strategy, including a potential recovery cycle toward 2027 and expansion through 2030. The company also reported progress on the Elite AF clinical trial and new FDA clearances. Boston Scientific Overshadowed by Hackers, Headwinds, and Lower Guidance
• Positive Sentiment: Several analysts still see upside: Robert W. Baird raised its price target to $51 and maintained an “outperform” rating, while BTIG and Needham retained “buy” ratings despite lowering their targets. Recent insider activity also showed purchases by executives.
• Neutral Sentiment: Analyst sentiment has become more cautious. Oppenheimer downgraded BSX to “market perform,” and JPMorgan cut its rating to “neutral” with a $46 price target, reflecting increased near-term uncertainty.
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by approximately $150 million and continues to affect operations, customer activity and the pace of recovery.
• Negative Sentiment: Boston Scientific lowered its full-year 2026 outlook to roughly 4.25% reported sales growth and adjusted EPS of $3.16–$3.18. Fourth-quarter adjusted EPS guidance of $0.77–$0.79 fell short of expectations, while sales are expected to decline 1%–3% year over year. Boston Scientific Crashes As Cybersecurity Attack Weighs On Guide
• Negative Sentiment: Investors are also concerned about contracting margins, weaker heart-device demand and challenging pricing conditions in China, which management indicated could make 2027 difficult.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.